NB

Nath Bio-Genes (India) Ltd

Q2 FY27Agricultural Food & other Products

Nath Bio-Genes (India) Q2 Results 2026: PAT ₹0 Cr (−84.7% YoY)

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Revenue
₹41Cr
−7.1% YoY
−87.6% QoQ
Net profit
₹0Cr
−84.7% YoY
−98.7% QoQ
Margin
11.36%
−2.6 pp YoY
+0.7 pp QoQ

Nath Bio-Genes (India) Ltd Q2 FY27 key numbers

Revenue
Revenue from operations for quarter ended 30.09.2026: Rs 4,074.30 lakhs.

As stated in Nath Bio-Genes (India) Ltd's Q2 FY27 results statement · published 15 Nov 2026. Reported figures, not investment advice.

Based on Nath Bio-Genes (India) Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹142
Market cap₹268 Cr
P/E7.9

The short version

Revenue from operations for quarter ended 30.09.2026: Rs 4,074.30 lakhs. EBITDA for the quarter ended 30/09/2026: ₹553.05 Lakhs.

From Nath Bio-Genes (India) Ltd's Q2 FY27 earnings-call transcript · updated 15 Nov 2026.

How did Nath Bio-Genes (India)'s revenue grow in the September 2026 quarter?

  • Revenue from operations for quarter ended 30.09.2026: Rs 4,074.30 lakhs
  • Revenue for same quarter last year (30.09.2025): Rs 4,384.96 lakhs
  • Year-on-year change: Decrease of Rs 310.66 lakhs (~7.08% decline)

What happened to Nath Bio-Genes (India)'s margins in Q2 FY27?

See what Nath Bio-Genes (India) Ltd said on profitability & margins — free account, 30 seconds.

What capex is Nath Bio-Genes (India) planning?

The following related points can be inferred from the financials: - Purchase of Fixed Assets: Rs. 667.99 lakhs (Consolidated, Half year ended 30.09.2026) indicating ongoing asset acquisition. - Increase in Non-Current Financial Assets and Other Non-Current Assets between March 2026 and September 2026 suggest investments. - The Standalone Statement shows a large Increase (Rs. 5,969.50 lakhs) under financing activities as "Increase/(Decrease) in Long Term Assets," which may imply asset acquisition or capex.

Top-ranked in Agricultural Food & other Products

Ranked on what management guided this quarter

Guidance-ranked
1Vintage Coffee
Rev 1Mar 1
Rev 1Mar 2
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Nath Bio-Genes (India) raising money or cutting debt?

See what Nath Bio-Genes (India) Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Nath Bio-Genes (India)'s order book?

See what Nath Bio-Genes (India) Ltd said on order book & pipeline — free account, 30 seconds.

Nath Bio-Genes (India) Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Nath Bio-Genes (India) Ltd Q2 FY27 results — key figures

Nath Bio-Genes (India) Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue41
Operating profit (EBITDA)5
Operating margin11.4%
Profit before tax1
Net profit (PAT)0
EPS (₹)0.22

Source: Nath Bio-Genes (India) Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹41 Cr, net profit ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

More Q2 FY27 results in Agricultural Food & other Products

All Q2 FY27 results | Agricultural Food & other Products rankings

Others in Agricultural Food & other Products this season

  • Shreeji Global (Q2 FY27)

    Total income for H1 FY27 was ₹423.95 Cr, up 43.9% YoY (from ₹294.56 Cr in H1 FY26). Key results statement takeaways from Shreeji Global FMCG Ltd's Q2 FY27 resul

  • KCK Industries (Q2 FY27)

    12.22%. Key results statement takeaways from KCK Industries Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • KN Agri Resource (Q2 FY27)

    Revenue from operations for the quarter ended 30.09.2026: INR 389.59 Crores (Consolidated) and INR 389.43 Crores (Standalone). Key results statement takeaways f

  • Mcleod Russel (Q2 FY27)

    8,811 lakhs, increased by 248% YoY (from Rs. Key results statement takeaways from Mcleod Russel India Ltd's Q2 FY27 results statement — and how it ranks against

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Nath Bio-Genes (India) Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Nath Bio-Genes (India) Ltd Q2 FY27 results?

Nath Bio-Genes (India) reported net profit of ₹0 Cr (−84.7% YoY) on revenue of ₹41 Cr (−7.1% YoY) in Q2 FY27.

What is Nath Bio-Genes (India) Ltd share price analysis?

Nath Bio-Genes (India) Ltd currently shows a neutral. The stock trades at a P/E of 7.9 with a market cap of ₹268 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Nath Bio-Genes (India) Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.